{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:04:56Z","timestamp":1791396296424,"version":"4.3.3"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Acute lymphoblastic leukaemia (ALL) is an aggressive haematolymphoid malignancy. The prognosis of ALL is excellent in paediatric population, however the outcome of relapse\/refractory disease is dismal. Adult ALL has less favourable prognosis and relapse\/refractory disease is not uncommonly encountered. Bortezomib is the first generation proteasome inhibitor licensed to treat plasma cell myeloma and mantle cell lymphoma with favourable side effect profile. Efficacy of bortezomib had been proven in other solid tumors. Clinical studies showed promising response for proteasome inhibitors in treating relapse\/refractory ALL. Thus, proteasome inhibitors are attractive alternative agents for research in treating ALL. In the review article, we will introduce different proteasome inhibitors and their difference in pharmacological properties. Moreover, the mechanism of action of proteasome inhibitors on ALL will be highlighted. Finally, results of various clinical studies on proteasome inhibitors in both paediatric and adult ALL will be discussed. This review article provides the insights on the use of proteasome inhibitors in treating ALL with a summary of mechanism of action in ALL which facilitates future research on its use to improve the outcome of ALL.<\/jats:p>","DOI":"10.3389\/fonc.2021.802832","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T11:47:54Z","timestamp":1640260074000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia"],"prefix":"10.3389","volume":"11","author":[{"given":"Chun-fung","family":"Sin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui-hei Marcus","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of Acute Lymphoblastic Leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1605071","article-title":"Recent Advances in the Treatment of Acute Lymphoblastic Leukemia","volume":"60","author":"Rafei","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B3","article-title":"Velcade (Bortezomib) Receives 2 New FDA Indications For Retreatment of Patients With Multiple Myeloma and for First-Line Treatment of Patients With Mantle-Cell Lymphoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208225","article-title":"Proteasome Inhibitor PS-341 Causes Cell Growth Arrest and Apoptosis in Human Glioblastoma Multiforme (GBM)","volume":"24","author":"Yin","year":"2005","journal-title":"Oncogene"},{"key":"B5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3892\/ijo.2012.1448","article-title":"Bortezomib Induces G2-M Arrest in Human Colon Cancer Cells Through ROS-Inducible Phosphorylation of ATM-Chk1","volume":"41","author":"Hong","year":"2012","journal-title":"Int J Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"105537","DOI":"10.1016\/j.phrs.2021.105537","article-title":"Pharmacology Differences Among Proteasome Inhibitors: Implications for Their Use in Clinical Practice","volume":"167","author":"Fogli","year":"2021","journal-title":"Pharmacol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome Inhibition in Multiple Myeloma: Head-To-Head Comparison of Currently Available Proteasome Inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-Analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular Mechanisms of Carfilzomib-Induced Cardiotoxicity in Mice and the Emerging Cardioprotective Role of Metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04234-9","article-title":"Ixazomib-Based Frontline Therapy in Patients With Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile With Those Reported in Clinical Trial: A Multi-Center Study","volume":"99","author":"Li","year":"2020","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06585.x","article-title":"Safety and Efficacy of Bortezomib in High-Risk and Elderly Patients With Relapsed Multiple Myeloma","volume":"137","author":"Richardson","year":"2007","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1021\/mp2004143","article-title":"Probing the Specificity and Activity Profiles of the Proteasome Inhibitors Bortezomib and Delanzomib","volume":"9","author":"Berkers","year":"2012","journal-title":"Mol Pharm"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2017.12.020","article-title":"Progress Curve Analysis of the Kinetics of Slow-Binding Anticancer Drug Inhibitors of the 20S Proteasome","volume":"639","author":"Hasinoff","year":"2018","journal-title":"Arch Biochem Biophys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1263842","article-title":"Phase I\/II Study of the Novel Proteasome Inhibitor Delanzomib (CEP-18770) for Relapsed and Refractory Multiple Myeloma","volume":"58","author":"Vogl","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3728","article-title":"A Phase Ib\/II Study of Oprozomib in Patients With Advanced Multiple Myeloma and Waldenstrom Macroglobulinemia","volume":"25","author":"Ghobrial","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"106172","DOI":"10.1016\/j.leukres.2019.106172","article-title":"Efficacy and Safety Results From a Phase 1b\/2, Multicenter, Open-Label Study of Oprozomib and Dexamethasone in Patients With Relapsed and\/or Refractory Multiple Myeloma","volume":"83","author":"Hari","year":"2019","journal-title":"Leuk Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14113","article-title":"Marizomib Irreversibly Inhibits Proteasome to Overcome Compensatory Hyperactivation in Multiple Myeloma and Solid Tumour Patients","volume":"174","author":"Levin","year":"2016","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bjh.14987","article-title":"A Phase 1 Clinical Trial Evaluating Marizomib, Pomalidomide and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma (NPI-0052-107): Final Study Results","volume":"180","author":"Spencer","year":"2018","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-686378","article-title":"Phase 1 Study of Marizomib in Relapsed or Relapsed and Refractory Multiple Myeloma: NPI-0052-101 Part 1","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200360200","article-title":"NF-Kappa B as a Therapeutic Target in Multiple Myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J Biol Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2173","article-title":"A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Leukemia: A Children\u2019s Oncology Group Study","volume":"13","author":"Horton","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.593271","article-title":"Successful T-Cell Acute Lymphoblastic Leukemia Treatment With Proteasome Inhibitor Bortezomib Based on Evaluation of Nuclear Factor-kappaB Activity","volume":"52","author":"Hu","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","article-title":"The Genetics and Mechanisms of T Cell Acute Lymphoblastic Leukaemia","volume":"16","author":"Belver","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nm1524","article-title":"Targeting the NF-kappaB Signaling Pathway in Notch1-Induced T-Cell Leukemia","volume":"13","author":"Vilimas","year":"2007","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.366","article-title":"Proteasome Inhibitors Exert Cytotoxicity and Increase Chemosensitivity via Transcriptional Repression of Notch1 in T-Cell Acute Lymphoblastic Leukemia","volume":"28","author":"Koyama","year":"2014","journal-title":"Leukemia"},{"key":"B28","article-title":"Differential Ex Vivo Activity of Bortezomib in Newly Diagnosed Paediatric Acute Lymphoblastic and Myeloblastic Leukaemia","volume":"30","author":"Szczepanek","year":"2010","journal-title":"Anticancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0186-z","article-title":"The Immunoproteasome and Thymoproteasome: Functions, Evolution and Human Disease","volume":"19","author":"Murata","year":"2018","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.092411","article-title":"Higher Ratio Immune Versus Constitutive Proteasome Level as Novel Indicator of Sensitivity of Pediatric Acute Leukemia Cells to Proteasome Inhibitors","volume":"98","author":"Niewerth","year":"2013","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","first-page":"10883","DOI":"10.1038\/s41598-021-90451-9","article-title":"Activity of Immunoproteasome Inhibitor ONX-0914 in Acute Lymphoblastic Leukemia Expressing MLL-AF4 Fusion Protein","volume":"11","author":"Jenkins","year":"2021","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bbcan.2007.10.003","article-title":"FoxO Tumor Suppressors and BCR-ABL-Induced Leukemia: A Matter of Evasion of Apoptosis","volume":"1785","author":"Jagani","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0605","article-title":"Proteasome Inhibition Causes Regression of Leukemia and Abrogates BCR-ABL-Induced Evasion of Apoptosis in Part Through Regulation of Forkhead Tumor Suppressors","volume":"69","author":"Jagani","year":"2009","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.11.6.14675","article-title":"Bortezomib Treatment Causes Remission in a Ph+ALL Patient and Reveals FoxO as a Theranostic Marker","volume":"11","author":"Dewar","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21062193","article-title":"The Current Genomic and Molecular Landscape of Philadelphia-Like Acute Lymphoblastic Leukemia","volume":"21","author":"Shiraz","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR Pathway Signaling Occurs in Human CRLF2-Rearranged B-Precursor Acute Lymphoblastic Leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22903","article-title":"The Critical Role of JNK in the ER-Mitochondrial Crosstalk During Apoptotic Cell Death","volume":"227","author":"Verma","year":"2012","journal-title":"J Cell Physiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular Mechanisms Mediating Antimyeloma Activity of Proteasome Inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3324\/haematol.2010.026997","article-title":"The Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Synergizes With Chemotherapeutic Agents, Ionizing Radiation and Proteasome Inhibitors in Pre-B Acute Lymphocytic Leukemia","volume":"96","author":"Saunders","year":"2011","journal-title":"Haematologica"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.73.011303.074134","article-title":"The Mammalian Unfolded Protein Response","volume":"74","author":"Schroder","year":"2005","journal-title":"Annu Rev Biochem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg227","article-title":"For Whom the Bell Tolls: Protein Quality Control of the Endoplasmic Reticulum and the Ubiquitin-Proteasome Connection","volume":"22","author":"Kostova","year":"2003","journal-title":"EMBO J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome Inhibitors Induce a Terminal Unfolded Protein Response in Multiple Myeloma Cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0250-z","article-title":"Mechanisms, Regulation and Functions of the Unfolded Protein Response","volume":"21","author":"Hetz","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6361","article-title":"Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute Lymphoblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP\/Grp78 and Turning on the Pro-Apoptotic NF-Kappab","volume":"7","author":"Buontempo","year":"2016","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-biochem-060815-014616","article-title":"Mechanisms and Functions of Spatial Protein Quality Control","volume":"86","author":"Sontag","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.03.008","article-title":"Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias Through MLL-Af4","volume":"25","author":"Liu","year":"2014","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.631594","article-title":"Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia","volume":"11","author":"Cheung","year":"2021","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular Basis of Resistance to Proteasome Inhibitors in Hematological Malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist Update"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.256","article-title":"Impaired Bortezomib Binding to Mutant Beta5 Subunit of the Proteasome is the Underlying Basis for Bortezomib Resistance in Leukemia Cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.138131","article-title":"Point Mutation of the Proteasome Beta5 Subunit Gene is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma\/Leukemia Line","volume":"326","author":"Lu","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2009.04.001","article-title":"Different Mutants of PSMB5 Confer Varying Bortezomib Resistance in T Lymphoblastic Lymphoma\/Leukemia Cells Derived From the Jurkat Cell Line","volume":"37","author":"Lu","year":"2009","journal-title":"Exp Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.04.013","article-title":"Overexpression of the PSMB5 Gene Contributes to Bortezomib Resistance in T-Lymphoblastic Lymphoma\/Leukemia Cells Derived From Jurkat Line","volume":"36","author":"Lu","year":"2008","journal-title":"Exp Hematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1756-8722-7-7","article-title":"Interferon-Gamma-Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance in Human Hematological Cell Lines","volume":"7","author":"Niewerth","year":"2014","journal-title":"J Hematol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0508","article-title":"Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias","volume":"10","author":"Cortes","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22456","article-title":"Phase I Study of Bortezomib Combined With Chemotherapy in Children With Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Therapeutic Advances in Childhood Leukemia (TACL) Consortium","volume":"55","author":"Messinger","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2235-z","article-title":"Bortezomib Combined With Standard Induction Chemotherapy in Japanese Children With Refractory Acute Lymphoblastic Leukemia","volume":"106","author":"Iguchi","year":"2017","journal-title":"Int J Hematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02714-x","article-title":"Bortezomib-Containing Therapy in Japanese Children With Relapsed Acute Lymphoblastic Leukemia","volume":"110","author":"Hasegawa","year":"2019","journal-title":"Int J Hematol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e28062","DOI":"10.1002\/pbc.28062","article-title":"Treatment of Children With Relapsed and Refractory Acute Lymphoblastic Leukemia With Mitoxantrone, Vincristine, Pegaspargase, Dexamethasone, and Bortezomib","volume":"67","author":"August","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e28241","DOI":"10.1002\/pbc.28241","article-title":"Outpatient Low Toxic Regimen With Bortezomib in Relapsed\/Refractory Acute Lymphoblastic Leukemia in Pediatrics and AYA Patients: Single-Center Mexican Experience","volume":"67","author":"Colunga-Pedraza","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000560","article-title":"Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance","volume":"38","author":"Yeo","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib With Chemotherapy Is Highly Active in Advanced B-Precursor Acute Lymphoblastic Leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14505","article-title":"The Combination of Bortezomib With Chemotherapy to Treat Relapsed\/Refractory Acute Lymphoblastic Leukaemia of Childhood","volume":"176","author":"Bertaina","year":"2017","journal-title":"Br J Haematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib Reinduction Chemotherapy in High-Risk ALL in First Relapse: A Report From the Children\u2019s Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16005","article-title":"Efficacy and Safety of a Bortezomib and Reduced-Intensity Cytarabine-Based Protocol, TMC ALLR1, for Relapsed Childhood ALL in India","volume":"186","author":"Roy","year":"2019","journal-title":"Br J Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15233","article-title":"An Effective Modestly Intensive Re-Induction Regimen With Bortezomib in Relapsed or Refractory Paediatric Acute Lymphoblastic Leukaemia","volume":"181","author":"Kaspers","year":"2018","journal-title":"Br J Haematol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1159\/000493252","article-title":"A Bortezomib-Based Protocol Induces a High Rate of Complete Remission With Minor Toxicity in Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"140","author":"Nachmias","year":"2018","journal-title":"Acta Haematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003368","article-title":"Bortezomib and Rituximab in De Novo Adolescent\/Adult CD20-Positive, Ph-Negative Pre-B-Cell Acute Lymphoblastic Leukemia","volume":"5","author":"Jain","year":"2021","journal-title":"Blood Adv"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1076930","article-title":"A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia","volume":"57","author":"Wartman","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26105","article-title":"Phase I Study of Escalating Doses of Carfilzomib With HyperCVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","volume":"96","author":"Jonas","year":"2021","journal-title":"Am J Hematol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.22037\/ijpr.2020.112692.13898","article-title":"Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-Cell Acute Lymphoblastic Leukemia Cell Line","volume":"18","author":"Hosseini","year":"2019","journal-title":"Iran J Pharm Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0188680","DOI":"10.1371\/journal.pone.0188680","article-title":"Anti-Leukemic Activity of Bortezomib and Carfilzomib on B-Cell Precursor ALL Cell Lines","volume":"12","author":"Takahashi","year":"2017","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10030665","article-title":"Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib Against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells","volume":"10","author":"Roeten","year":"2021","journal-title":"Cells"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.406","article-title":"Management of Adult Ph-Positive Acute Lymphoblastic Leukemia","volume":"2015","author":"Chiaretti","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13268","article-title":"Prospective Evaluation of Minimal Residual Disease Monitoring to Predict Prognosis of Adult Patients With Ph-Negative Acute Lymphoblastic Leukemia","volume":"103","author":"Nagafuji","year":"2019","journal-title":"Eur J Haematol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17424","article-title":"Minimal Residual Disease Level Determined by Flow Cytometry Provides Reliable Risk Stratification in Adults With T-Cell Acute Lymphoblastic Leukaemia","volume":"193","author":"Wang","year":"2021","journal-title":"Br J Haematol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-Cell Precursor Leukaemia: A Subtype of Very High-Risk Acute Lymphoblastic Leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1182\/blood-2013-03-491092","article-title":"Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Acute Lymphoblastic Leukemia","volume":"122","author":"Van Vlierberghe","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.802832\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T11:48:04Z","timestamp":1640260084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.802832\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":78,"alternative-id":["10.3389\/fonc.2021.802832"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.802832","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"article-number":"802832"}}